- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Generic azelastine ophthalmic solution available
The FDA has granted approval for an abbreviated new drug application to market a generic version of azelastine ophthalmic solution 0.05% (Optivar, Meda Pharmaceuticals), according to Sun Pharmaceutical Industries.
Mumbai, India-The FDA has granted approval for an abbreviated new drug application (ANDA) to market a generic version of azelastine ophthalmic solution 0.05% (Optivar, Meda Pharmaceuticals), according to Sun Pharmaceutical Industries.
Azelastine is a selective antihistamine for the treatment of itching of the eyes associated with allergic conjunctivitis.
Established in 1983, Sun Pharmaceutical Industries manufactures and markets several pharmaceutical formulations as branded generics as well as generics in India, the United States, and several other markets across the world.
